Corrigendum to "Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy" [Reprod Toxicol 24 (2007) 414-416] (DOI:10.1016/j.reprotox.2007.07.002);Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy

Reproductive Toxicology

Volumn 24, Issue 3-4, 2007, Pages 414-416

  Labarga, Pablo ^b   Pinilla, Javier ^a   Cachorro, Iban ^c   del Prado, Yolanda Ruiz ^a  

^a HOSPITAL SAN PEDRO   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Hospital de San Eloy   (Spain)

Author keywords

Case report; Drug effects; Infant; Pregnancy outcome; Ribavirin

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; ZIDOVUDINE;

ARTICLE; CASE REPORT; CONGENITAL MALFORMATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FETUS MALFORMATION; GESTATION PERIOD; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; NONHUMAN; PREGNANT WOMAN;

HEPATITIS C VIRUS;

EID: 35548968066     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2008.08.005     Document Type: Erratum

References (11)

1. Haggstrom J., Adriansson M., Hybbinette T., Harnby E., and Thorbert G. Two cases of CML treated with alpha-interferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum. Eur J Haematol 57 1 (1996) 101-102
2. Watanabe M., Kohge N., Akagi S., Uchida Y., Sato S., and Kinoshita Y. Congenital anomalies in a child born from a mother with interferon-treated chronic hepatitis B. Am J Gastroenterol 96 5 (2001) 1668-1669
3. Ferm V.H., Willhite C., and Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 17 1 (1978) 93-101
4. Kilham L., and Ferm V.H. Congenital anomalies induced in hamster embryos with ribavirin. Science 195 4276 (1977) 413-414
5. Kochhar D.M., Penner J.D., and Knudsen T.B. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 52 1 (1980) 99-112
6. Mishkin D., and Deschenes M. Conception soon after discontinuing interferon/ribavirin therapy: a successful outcome. Am J Gastroenterol 96 7 (2001) 2285-2286
7. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17):1-19.
8. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 5 (1981) 431-435
9. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States 12/10/2006. Available at http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf, http://www aidsinfo nih gov/.
10. De Santis M., Carducci B., Cavaliere A.F., De Santis L., Lucchese A., Straface G., et al. Paternal exposure to ribavirin: pregnancy and neonatal outcome. Antivir Ther 8 1 (2003) 73-75
11. Hegenbarth K., Maurer U., Kroisel P.M., Fickert P., Trauner M., and Stauber R.E. No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. Am J Gastroenterol 96 7 (2001) 2286-2287